ClinConnect ClinConnect Logo
Search / Trial NCT05497609

The Muscle in Children With Cerebral Palsy - Longitudinal Exploration of Microscopic Muscle Structure.

Launched by EVA PONTEN · Aug 9, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Cerebral Palsy Upper Limb Lower Limb Muscle Biopsy Botulinum Toxin Type A

ClinConnect Summary

This clinical trial is studying how muscle structure changes over time in children with cerebral palsy (CP), a condition that affects movement due to brain injury. CP can cause tightness in muscles and problems with coordination, which may lead to the muscles becoming shorter and joints becoming stiff. Researchers want to see if a common treatment involving botulinum toxin injections, along with physical training and splinting, can improve muscle health and function. They will take small samples of muscle tissue (biopsies) from participants at different times to look for signs of muscle growth and adaptation.

Children aged 2 to 18 with cerebral palsy or acquired brain injury may be eligible to join this study, but those with progressive neurological diseases will not qualify. Participants will receive standard care, and their muscle samples will be collected before treatment starts and again after 4-6 months, 12 months, and 24 months to track changes. The findings from this trial could help develop better treatments to prevent muscle and joint problems in kids with CP.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Cerebral Palsy, Aquired Brain Injury
  • Exclusion Criteria:
  • Progressive neural disease

About Eva Ponten

Eva Ponten is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a commitment to rigorous scientific standards and ethical practices, Eva Ponten collaborates with leading research institutions and healthcare professionals to conduct high-quality clinical trials. The organization emphasizes transparency, safety, and integrity in all its endeavors, aiming to contribute significantly to the development of new treatments that address unmet medical needs. Through strategic partnerships and a patient-centered approach, Eva Ponten strives to accelerate the delivery of groundbreaking therapies to the market.

Locations

Stockholm, , Sweden

Patients applied

0 patients applied

Trial Officials

Eva M Pontén, MD PhD

Principal Investigator

Karolinska Institutet

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials